TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Trump Says Anthropic No Longer Seen as National Security Threat 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
PARIS, Jan. 29, 2016 -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today its financial reporting calendar for 2016.
Financial publications will be released prior to the opening of the Paris stock exchange. This calendar is indicative and subject to change.
| -- 2015 Full-Year Results | March 7, 2016 | |||
| -- Shareholders’ AGM | April 12, 2016 | |||
| -- 2016 Half-Year results | October 14, 2016 |
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.
